Key precautions include monitoring for hyperglycemia, diarrhea, cutaneous reactions, and embryo-fetal toxicity, with specific management protocols.

Critical Monitoring and Risk Mitigation

TRUQAP necessitates rigorous monitoring: fasting glucose and HbA1C must be assessed pre-treatment and periodically, with hyperglycemia managed via anti-diabetic agents or dose adjustments. Diarrhea (Grade ≥2) requires antidiarrheals, hydration, and potential dose withholding. Cutaneous reactions (e.g., erythema multiforme, DRESS) warrant dermatologic consultation and corticosteroid therapy. Embryo-fetal toxicity risks mandate effective contraception in reproductive-aged patients (1 month post-treatment for females, 4 months for males). Concomitant strong/moderate CYP3A inhibitors or inducers are contraindicated or require dose reduction. Pre-existing insulin-dependent diabetes or severe hepatic impairment lack safety data. Proactive patient counseling on symptom recognition (e.g., hyperglycemia signs) is critical.